Premium
Head and neck presentations of B‐NHL and B‐AL in children/adolescents: Experience of the LMB89 study
Author(s) -
Lervat Cyril,
Auperin Anne,
Patte Catherine,
Méchinaud Françoise,
Leverger Guy,
Nelken Brigitte,
Bertrand Yves,
Baruchel Andre,
Coze Carole,
Munzer Martine,
Lacombe M. J. Terrier,
Bergeron Christophe
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24707
Subject(s) - medicine , stage (stratigraphy) , lymphoma , group b , b symptoms , disease , epidemiology , gastroenterology , head and neck , multivariate analysis , pediatrics , surgery , paleontology , biology
Purpose Describe the epidemiology, clinical profiles and outcomes associated with head and neck (H&N) involvement in children/adolescents with B‐cell non‐Hodgkin lymphoma (B‐NHL). Methods Analysis of children/adolescents with H&N B‐NHL prospectively enrolled in the SFOP LMB‐89 trial (July 1989–June 1996). Results One hundred and twelve of 561 patients (20%) had H&N involvement. The mean age of the patients was 8.4 years. Murphy staging differed between the H&N patients and the others ( P < 0.0001): 9% versus 5% of the patients presented with stage I disease, 36% versus 11% presented with stage II disease, 12% versus 59% presented with stage III disease, 17% versus 10% with stage IV disease and 27% versus 16% with B‐AL. Twenty‐nine H&N patients (26%) had CNS involvement at diagnosis versus 8.5% in the group without H&N involvement ( P < 0.0001). Patients were treated according to the LMB89 protocol: 3 H&N patients were allocated to group A, 70 to group B and 39 to group C. Ninety‐seven percent of H&N patients achieved CR and event‐free and overall survival at 4 years was 95.5% (5 deaths in patients with CNS disease). On multivariate analysis, EFS was significantly better in H&N patients than in non‐H&N patients ( P = 0.021), but not OS ( P = 0.11). Conclusion The H&N site is the second most common location for B‐NHL at diagnosis and is more frequently associated with disseminated disease and CNS involvement than other sites. However, outcomes are no worse for these patients than for the rest of the population. Pediatr Blood Cancer 2014;61:473–478. © 2013 Wiley Periodicals, Inc.